Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation

  • Ginex, Tiziana
  • Marco-Marín, Clara
  • Wieczor, Milosz
  • Mata, Carlos P.
  • Krieger, James
  • López-Redondo, Marisa
  • Francés-Gómez, Clara
  • Ruiz-Rodríguez, Paula
  • Melero, Roberto
  • Sorzano, Carlos Óscar S.
  • Martínez, Marta
  • Gougeard, Nadine
  • Forcada-Nadal, Alicia
  • Zamora-Caballero, Sara
  • Gozalbo-Rovira, Roberto
  • Sanz-Frasquet, Carla
  • Bravo, Jerónimo
  • Rubio, Vicente
  • Marina, Alberto
  • Geller, Ron
  • Comas, Iñaki
  • Gil, Carmen
  • Coscollá, Mireia
  • Orozco, Modesto
  • Llácer, José Luis
  • Carazo, José M.
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has now reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness., This research work was supported by the European Commission–NextGenerationEU through the CSIC Global Health Platform. Additionally, authors would like to acknowledge economic support from the Spanish Ministry of Science and Innovation through Grants: PID2019-104757RB-I00 funded by MCIN/AEI/ 10.13039/501100011033, RTI2018-094399-A-I00, and “ERDF A way of making Europe”, by the “European Union”, Grant SEV 2017-0712 funded by MCIN/AEI /10.13039/501100011033, the “Comunidad Autónoma de Madrid" through Grant: S2017/BMD3817, and the European Union (EU) and Horizon 2020 through grants: Marie-Curie Fellowship EnLaCES (MSCA IF 2020, Proposal: 101024130) (to JK), HighResCells (ERC - 2018 - SyG, Proposal: 810057), and iNEXT-Discovery (Proposal: 871037). AM, VR, JB and JLL are funded by CIBERER-ISCIII (proposal: COV20/00437), Fondo Supera COVID-19 (proposal: CSICCOVID19-082), Banco Santander (Proposal: BlockAce), and CSIC PTI Salud Global (Proposal: 202080E110). VR is funded by the Spanish Ministry of Science and Innovation through Grant PID2020-120322RB-C21. IC is funded by project PID2019-104477RB-100, Fondo COVID COV20/00140 and ERC CoG 101001038. MC is funded by the RyC program from the Spanish Ministry of Science and Innovation, the Generalitat Valenciana (SEJI/2019/011)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Genomic approaches for tuberculosis management and control, Deploying sequencing advances to the clinic

  • Comas, Iñaki
  • López, Mariana G.
  • Chiner-Oms, Álvaro
  • Farhat, Maha R.
  • Semuto Ngabonziza, Jean Claude
  • Campos, Josefina
  • Moreno-Molina, Miguel
18 páginas, 2 figuras., Research at IC laboratory is funded by European Research Council (TB-RECONNECT Program Grant 101001038), Ministerio de Ciencia (Spanish Government) Project PID2019-104477RB-I00, European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). JSN is funded by research project ‘Innovate to reduce rifampicin resistance tuberculosis in Rwanda and beyond’ with financial support from ITM’s SOFI programme supported by the Flemish Government, Science & Innovation. ACO is supported by a RyC grant RYC2021‐031461‐I funded by MCIN/AEI/ 10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

VIPERA: Viral Intra-Patient Evolution Reporting and Analysis

  • Álvarez-Herrera, Miguel
  • Sevilla, Jordi
  • Ruiz-Rodríguez, Paula
  • Vergara, Andrea
  • Vila, Jordi
  • Cano-Jiménez, Pablo
  • González-Candelas, Fernando
  • Comas, Iñaki
  • Coscollá, Mireia
Viral mutations within patients nurture the adaptive potential of SARS-CoV-2 during chronic infections, which are a potential source of variants of concern. However, there is no integrated framework for the evolutionary analysis of intra-patient SARS-CoV-2 serial samples. Herein we describe VIPERA (Viral Intra-Patient Evolution Reporting and Analysis), a new software that integrates the evaluation of the intra-patient ancestry of SARS-CoV-2 sequences with the analysis of evolutionary trajectories of serial sequences from the same viral infection. It has been validated using positive and negative control datasets and successfully applied to a novel case, contributing to easy and automatic analysis of intra-patient SARS-CoV-2 sequences., This work was funded by the Spanish Ministry of Science (CNS2022-135116) and the European Commission – NextGenerationEU (Regulation EU 2020/2094), through the Global Health Platform (PTI+ Salud Global) of the Spanish National Research Council (CSIC). MAH and PRR are supported by the PTI+ Salud Global. JS is supported by the CSIC’s JAE intro programme. FGC was funded by project PID2021-127010OB-I00 from the Spanish Ministry of Science and CIPROM2021-053 from the Generalitat Valenciana. IC is funded by the European Research Council (101001038-TB640 RECONNECT) and the Spanish Ministry of Economy, Industry and Competitiveness (PID2019- 104477RB-I00). MC is funded by the Spanish Ministry of Science (PID2021-123443OB-I00)., No